Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TONIC-3: Tiragolumab combinations in advanced TNBC
NCT06342037Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2024
- Primary completion
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of tiragolumab in triple-negative breast cancer (TNBC), sponsored by Netherlands Cancer Institute. Started Jun 2024; status: recruiting.
02
Drugs
tiragolumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06342037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06342037.